Last reviewed 2026-06-02 · How we verify

KYN-5356 High Dose

Kynexis B.V. · Phase 2 active Small molecule ✓ Verified Jun 2026

KYN-5356 High Dose is a Small molecule drug developed by Kynexis B.V.. It is currently in Phase 2 development.

KYN-5356 is being studied in a clinical trial for its potential to treat Cognitive Impairment Associated With Schizophrenia (CIAS). The study is evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of KYN-5356 in adults with CIAS.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	KYN-5356 High Dose
Sponsor	Kynexis B.V.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KYN-5356 High Dose CI brief — competitive landscape report
KYN-5356 High Dose updates RSS · CI watch RSS
Kynexis B.V. portfolio CI

Frequently asked questions about KYN-5356 High Dose

What is KYN-5356 High Dose?

KYN-5356 High Dose is a Small molecule drug developed by Kynexis B.V..

Who makes KYN-5356 High Dose?

KYN-5356 High Dose is developed by Kynexis B.V. (see full Kynexis B.V. pipeline at /company/kynexis-b-v).

What development phase is KYN-5356 High Dose in?

KYN-5356 High Dose is in Phase 2.

Manufacturer: Kynexis B.V. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing